Clinical Scorecard: Understanding ALS, commonly referred to as Lou Gehrig's disease
At a Glance
Category
Detail
Condition
Amyotrophic lateral sclerosis (ALS) is a fatal nervous system disease causing progressive loss of muscle control due to nerve cell death in the brain and spinal cord.
Key Mechanisms
Degeneration and death of upper and lower motor neurons leading to muscle paralysis, affecting mobility, speech, swallowing, and breathing.
Target Population
Primarily adults aged 40 to 60, slightly more common in men than women.
Care Setting
Neurology clinics, specialized ALS centers, and multidisciplinary care involving physical therapy, respiratory support, and palliative care.
Key Highlights
ALS causes progressive muscle weakness, twitching, cramps, and eventual paralysis.
No definitive diagnostic test; diagnosis relies on clinical evaluation, lab tests, and imaging.
Riluzole is approved to potentially extend survival or delay respiratory support; no cure exists.
Guideline-Based Recommendations
Diagnosis
Perform thorough physical examination focusing on motor neuron signs.
Use laboratory tests and imaging of brain and spinal cord to exclude other conditions.
Identify clinical signs such as muscle twitching, cramps, spasticity, and diminished coordination.
Management
Prescribe riluzole to potentially extend survival in early disease stages.
Use symptomatic treatments to manage muscle cramps, spasticity, and respiratory difficulties.
Implement supportive devices such as braces, wheelchairs, speech synthesizers, and feeding tubes as needed.
Monitoring & Follow-up
Regularly assess respiratory function and swallowing ability to anticipate complications.
Monitor progression of muscle weakness and functional status.
Adjust supportive care and interventions based on symptom evolution.
Risks
Progressive respiratory failure is the leading cause of death.
Risk of choking and aspiration due to impaired swallowing.
Potential complications from immobility and respiratory insufficiency.
Patient & Prescribing Data
Adults diagnosed with ALS, typically aged 40-60 years.
Riluzole may extend survival or delay need for ventilatory support; other medications focus on symptom control; Relyvrio was withdrawn from the U.S. market in 2024.
Clinical Best Practices
Early recognition of subtle symptoms such as muscle twitching and weakness.
Comprehensive multidisciplinary care including neurology, respiratory therapy, and nutrition.
Proactive planning for respiratory support and nutritional interventions.
